Ajay Yadlapati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ajay Yadlapati has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Mark Gajjar
Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
4 shared publicationsChristopher Groh
Division of Cardiology, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 676 N. St. Clair Street, Suite 600, Chicago, IL, 60611-2996, USA
3 shared publicationsJyothy J. Puthumana
Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
3 shared publicationsAlexander P. Taylor
Division of Cardiology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois
2 shared publicationsJames D. Thomas
Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
2 shared publicationsJeremy Collins
Department of Radiology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL
2 shared publications
Latest Publications
- 6 March 2019
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (7) , 1382-1384
Novel shunt modification with an adjustable stent‐embedded “fenestrated” septal occluder in a patient with pulmonary hypertension
A 60‐year‐old woman with progressive dyspnea and cyanosis, O2‐dependent pulmonary hypertension despite optimal medical therapy and remote atrial septostomy presented with worsening cyanosis and right‐to‐left shunting. The creation of a “fenestrated” ASD closure device with the insertion of a peripheral stent through an AMPLATZER™ ASD closure device was deployed to minimize right to left shunting and allow for enlargement of the shunt if needed. This case demonstrates the benefit of diminishing a right to left shunt with a self‐fabricated fenestrated AMPLATZER device to improve symptoms in pulmonary hypertension patients with a pre‐existing ASD.
- 6 March 2019
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (7) , 1382-1384
Novel shunt modification with an adjustable stent‐embedded “fenestrated” septal occluder in a patient with pulmonary hypertension
A 60‐year‐old woman with progressive dyspnea and cyanosis, O2‐dependent pulmonary hypertension despite optimal medical therapy and remote atrial septostomy presented with worsening cyanosis and right‐to‐left shunting. The creation of a “fenestrated” ASD closure device with the insertion of a peripheral stent through an AMPLATZER™ ASD closure device was deployed to minimize right to left shunting and allow for enlargement of the shunt if needed. This case demonstrates the benefit of diminishing a right to left shunt with a self‐fabricated fenestrated AMPLATZER device to improve symptoms in pulmonary hypertension patients with a pre‐existing ASD.
- 23 March 2017
- Published by SAGE Publications in Perfusion
- Vol. 32 (7) , 529-537
Global longitudinal strain from resting echocardiogram is associated with long-term adverse cardiac outcomes in patients with suspected coronary artery disease
Purpose: Measuring myocardial strain using two-dimensional speckle tracking echocardiography has emerged as a new tool to identify subclinical ventricular dysfunction. Abnormal strain has been shown to have superior sensitivity compared with dobutamine stress echocardiography for viability assessment; however, there is a paucity of data regarding the prediction of long-term major adverse cardiac events. We compared the prognostic ability of both global longitudinal strain (GLS) from resting echocardiograms to regional wall motion score index (WMSI) from stress echocardiograms in their ability to predict long-term major adverse cardiac events. Methods: Patients referred for stress echocardiography, who also underwent coronary angiography within 3 months of stress echo (n=122), were enrolled. Patients with reduced ejection fractions (<40%) were excluded. Patients were followed for a median of 3.4 years for major adverse cardiac events, readmissions and repeat cardiac testing. Results: Patients with abnormal GLS (GLS <16.8%) from the resting echocardiogram obtained as part of the exercise echocardiogram experienced a significantly shorter time to major adverse cardiac events (p=0.026), first cardiovascular hospitalization and repeat cardiac testing (p=0.0011) compared to those with normal GLS. Abnormal GLS appears to be a better predictor than abnormal WMSI in predicting major adverse cardiac events (p=0.174) and time to first cardiovascular hospitalization or repeat cardiac testing (p=0.0093). Conclusion: GLS may be a better predictor of long-term major adverse cardiac events, readmissions and repeat cardiac testing than WMSI in patients undergoing stress echocardiography.
- 23 March 2017
- Published by SAGE Publications in Perfusion
- Vol. 32 (7) , 529-537
Global longitudinal strain from resting echocardiogram is associated with long-term adverse cardiac outcomes in patients with suspected coronary artery disease
Purpose: Measuring myocardial strain using two-dimensional speckle tracking echocardiography has emerged as a new tool to identify subclinical ventricular dysfunction. Abnormal strain has been shown to have superior sensitivity compared with dobutamine stress echocardiography for viability assessment; however, there is a paucity of data regarding the prediction of long-term major adverse cardiac events. We compared the prognostic ability of both global longitudinal strain (GLS) from resting echocardiograms to regional wall motion score index (WMSI) from stress echocardiograms in their ability to predict long-term major adverse cardiac events. Methods: Patients referred for stress echocardiography, who also underwent coronary angiography within 3 months of stress echo (n=122), were enrolled. Patients with reduced ejection fractions (<40%) were excluded. Patients were followed for a median of 3.4 years for major adverse cardiac events, readmissions and repeat cardiac testing. Results: Patients with abnormal GLS (GLS <16.8%) from the resting echocardiogram obtained as part of the exercise echocardiogram experienced a significantly shorter time to major adverse cardiac events (p=0.026), first cardiovascular hospitalization and repeat cardiac testing (p=0.0011) compared to those with normal GLS. Abnormal GLS appears to be a better predictor than abnormal WMSI in predicting major adverse cardiac events (p=0.174) and time to first cardiovascular hospitalization or repeat cardiac testing (p=0.0093). Conclusion: GLS may be a better predictor of long-term major adverse cardiac events, readmissions and repeat cardiac testing than WMSI in patients undergoing stress echocardiography.
- 22 December 2016
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 40 (1) , 67-68
New Heart…New Rhythm
- 22 December 2016
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 40 (1) , 67-68
New Heart…New Rhythm
- 1 August 2016
- Published by Texas Heart Institute Journal in Texas Heart Institute Journal
- Vol. 43 (4) , 287-290
Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future
Article Citation: Ramsey M. Wehbe and Ajay Yadlapati (2016) Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future. Texas Heart Institute Journal: August 2016, Vol. 43, No. 4, pp. 287-290. doi: http://dx.doi.org/10.14503/THIJ-16-5785
- 1 August 2016
- Published by Texas Heart Institute Journal in Texas Heart Institute Journal
- Vol. 43 (4) , 287-290
Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future
Article Citation: Ramsey M. Wehbe and Ajay Yadlapati (2016) Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future. Texas Heart Institute Journal: August 2016, Vol. 43, No. 4, pp. 287-290. doi: http://dx.doi.org/10.14503/THIJ-16-5785
- Open Access
- 22 December 2015
- Published by Wiley in Clinical Cardiology
- Vol. 39 (1) , 41-47
Statin Use and Aneurysm Risk in Patients With Bicuspid Aortic Valve Disease
Background: No medical therapy has been proven to prevent the progression of aortic dilatation in bicuspid aortic valve (BAV) disease, and prophylactic aortic surgery remains the mainstay of treatment.Hypothesis: Among patients with BAV disease who are referred for surgery, preoperative statin use is associated with decreased odds of ascending aortic dilatation.Methods: We reviewed all BAV patients who underwent aortic valve and/or aortic surgery at our center between April 2004 and December 2013. Aortic diameter (AD), defined as the maximum ascending aortic dimension, was determined by magnetic resonance imaging, computed tomography, or echocardiography. Patients were divided into 2 groups: maximal AD P = 0.029).Conclusions: In a retrospective study of BAV patients referred for surgery, preoperative statin use was associated with lower odds of clinically significant ascending aortic dilatation.
- 22 December 2015
- Published by Wiley in Clinical Cardiology
- Vol. 39 (1) , 41-47
Open AccessStatin Use and Aneurysm Risk in Patients With Bicuspid Aortic Valve Disease
Background: No medical therapy has been proven to prevent the progression of aortic dilatation in bicuspid aortic valve (BAV) disease, and prophylactic aortic surgery remains the mainstay of treatment.Hypothesis: Among patients with BAV disease who are referred for surgery, preoperative statin use is associated with decreased odds of ascending aortic dilatation.Methods: We reviewed all BAV patients who underwent aortic valve and/or aortic surgery at our center between April 2004 and December 2013. Aortic diameter (AD), defined as the maximum ascending aortic dimension, was determined by magnetic resonance imaging, computed tomography, or echocardiography. Patients were divided into 2 groups: maximal AD P = 0.029).Conclusions: In a retrospective study of BAV patients referred for surgery, preoperative statin use was associated with lower odds of clinically significant ascending aortic dilatation.